XFOR X4 PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, X4 PHARMACEUTICALS INC reported revenue of $2.40M (up 41.2% from a year earlier), net income of −$16.2M and diluted EPS of −$0.13; over the last four quarters revenue was $8.80M and net income −$90.1M; for the fiscal year ended December 2025 revenue was $6.50M, up 150.0% on the year before.

XFOR annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $6.50M, gross profit n/a, operating income −$86.9M, net income −$79.2M (margin -1218.4%), EPS −$1.87
• Fiscal year ended Dec 2024: revenue $2.60M, gross profit n/a, operating income −$36.4M, net income −$37.5M (margin -1440.4%), EPS −$5.59
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$108M, net income −$101M (margin n/a), EPS −$17.07
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$87.6M, net income −$93.9M (margin n/a), EPS −$1.52
• Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$85.1M, net income −$88.7M (margin n/a), EPS −$3.99

XFOR quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $2.40M (up 41.2% year over year), net income −$16.2M, EPS −$0.13
• Quarter ended Mar 31, 2026: revenue $2.50M (up 177.8% year over year), net income −$20.2M, EPS −$0.16
• Quarter ended Dec 31, 2025 (from the annual report): revenue $2.33M (up 58.0% year over year), net income −$23.9M, EPS $2.25
• Quarter ended Sep 30, 2025: revenue $1.57M (up 179.6% year over year), net income −$29.8M, EPS −$0.69
• Quarter ended Jun 30, 2025: revenue $1.70M (up 202.0% year over year), net income −$25.7M, EPS −$3.47
• Quarter ended Mar 31, 2025: revenue $900K, net income $282K, EPS $0.04
• Quarter ended Dec 31, 2024 (from the annual report): revenue $1.48M, net income −$39.8M, EPS −$5.91
• Quarter ended Sep 30, 2024: revenue $560K, net income −$36.7M, EPS −$5.48
• Quarter ended Jun 30, 2024: revenue $563K, net income $90.8M, EPS $13.57
• Quarter ended Mar 31, 2024: revenue $0, net income −$51.8M, EPS −$7.77
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$19.1M, EPS −$16.57
• Quarter ended Sep 30, 2023: revenue $0, net income −$2.31M, EPS −$0.01
• Quarter ended Jun 30, 2023: revenue $0, net income −$55.7M, EPS −$0.33
• Quarter ended Mar 31, 2023: revenue n/a, net income −$24.0M, EPS −$0.16
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$29.1M, EPS $0.06
• Quarter ended Sep 30, 2022: revenue n/a, net income −$21.6M, EPS −$0.26
• Quarter ended Jun 30, 2022: revenue n/a, net income −$21.2M, EPS −$0.60
• Quarter ended Mar 31, 2022: revenue n/a, net income −$22.0M, EPS −$0.72
• Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$30.2M, EPS −$1.19
• Quarter ended Sep 30, 2021: revenue $0, net income −$20.2M, EPS −$0.76

XFOR cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$85.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$131M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$96.5M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow −$77.1M, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow −$70.9M, share buybacks $2.00M

XFOR balance sheet

• Jun 30, 2026: cash $195M, total assets $253M, total liabilities $97.6M, shareholders' equity $155M
• Mar 31, 2026: cash $217M, total assets $270M, total liabilities $102M, shareholders' equity $168M
• Dec 31, 2025: cash $217M, total assets $290M, total liabilities $104M, shareholders' equity $186M
• Sep 30, 2025: cash $69.6M, total assets $164M, total liabilities $102M, shareholders' equity $61.6M
• Jun 30, 2025: cash $39.2M, total assets $105M, total liabilities $101M, shareholders' equity $3.97M
• Mar 31, 2025: cash $40.3M, total assets $130M, total liabilities $107M, shareholders' equity $22.9M
• Dec 31, 2024: cash $55.7M, total assets $146M, total liabilities $124M, shareholders' equity $22.1M
• Sep 30, 2024: cash $97.4M, total assets $178M, total liabilities $119M, shareholders' equity $59.6M

What is XFOR's revenue?

X4 PHARMACEUTICALS INC reported $8.80M of revenue over its last four quarters, through June 30, 2026.

Is XFOR profitable?

No. X4 PHARMACEUTICALS INC lost $90.1M over the last four quarters.

What is XFOR's EPS?

Diluted earnings per share over the last four quarters were $1.27; −$0.13 in the latest quarter.

XFOR ownership and insider trades · All stocks